Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma
暂无分享,去创建一个
J. Wargo | C. Liu | P. Hwu | Z. Cooper | J. Roszik | Chandrani Chattopadhyay | E. Grimm | Yong Qin | S. Ekmekcioglu | Y. Hashimoto | Chengwen Liu
[1] S. Pastoreková,et al. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib. , 2016, Molecular medicine reports.
[2] Yuhua Lin,et al. HGF expression induced by HIF‐1α promote the proliferation and tube formation of endothelial progenitor cells , 2015, Cell biology international.
[3] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[4] Chang S. Chan,et al. Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD , 2014, Oncotarget.
[5] M. Mazzone,et al. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment , 2014, Oncogene.
[6] Jason Li,et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. , 2014, Cancer discovery.
[7] R. Salgia,et al. Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt Signaling in Hepatocyte Growth Factor (HGF)-mediated Lamellipodia Formation, Reactive Oxygen Species (ROS) Generation, and Motility of Lung Endothelial Cells* , 2014, The Journal of Biological Chemistry.
[8] R. Pazdur,et al. U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive , 2014, Clinical Cancer Research.
[9] F. Briest,et al. PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms , 2014, Theranostics.
[10] A. Weeraratna,et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.
[11] J. Sosman,et al. Impact of MET expression on outcome in BRAFV600E/K advanced melanoma , 2013, Histopathology.
[12] S. Corso,et al. Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. , 2013, Cancer discovery.
[13] T. Ochiya,et al. Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β , 2013, Scientific Reports.
[14] T. Kondo,et al. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system , 2013, Proteomics.
[15] Fabio Fumarola,et al. Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma , 2013, Clinical Cancer Research.
[16] Chandrani Chattopadhyay,et al. Association of activated c‐Met with NRAS‐mutated human melanomas , 2012, International journal of cancer.
[17] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.
[18] Jane Fridlyand,et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.
[19] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[20] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[21] Hideo Namiki,et al. The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. , 2011, Biomaterials.
[22] Sarat Chandarlapaty,et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.
[23] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. E. Vincent,et al. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer , 2011, British Journal of Cancer.
[25] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[26] Marc Vidal,et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.
[27] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[28] Kazuya Negishi,et al. Phosphorescent light-emitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals , 2010, BiOS.
[29] D. Feng,et al. Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1 , 2009, Molecular Biology Reports.
[30] P. Bendinelli,et al. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. , 2009, Carcinogenesis.
[31] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[32] P. Várnai,et al. c-Met Must Translocate to the Nucleus to Initiate Calcium Signals*♦ , 2008, Journal of Biological Chemistry.
[33] Kenneth M. Yamada,et al. Modeling Tissue Morphogenesis and Cancer in 3D , 2007, Cell.
[34] M. Westphal,et al. Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migration , 2007, International journal of cancer.
[35] P. Vaupel,et al. Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.
[36] L. Broemeling,et al. Tumor iNOS predicts poor survival for stage III melanoma patients , 2006, International journal of cancer.
[37] Ravi Salgia,et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.
[38] Jens Overgaard,et al. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer , 2004, Acta oncologica.
[39] J. Reis-Filho,et al. Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas , 2003, Oncology.
[40] C. Koch,et al. Prognostic significance of tumor oxygenation in humans. , 2003, Cancer letters.
[41] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[42] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[43] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[44] M. Dewhirst,et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[45] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[46] Peter Vaupel,et al. Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? , 2013, Advances in experimental medicine and biology.
[47] O. Cuvillier,et al. Hypoxia, therapeutic resistance, and sphingosine 1-phosphate. , 2013, Advances in cancer research.
[48] John W Haycock,et al. 3D cell culture: a review of current approaches and techniques. , 2011, Methods in molecular biology.